<DOC>
	<DOCNO>NCT00720122</DOCNO>
	<brief_summary>Adolescents young adult anorexia nervosa ( AN ) high risk low bone mineral density time healthy adolescent rapidly accrue bone , implication peak bone mass fracture risk later life . They also deficient insulin-like growth factor 1 ( IGF-1 ) , bone trophic factor make liver response growth hormone ( GH ) , despite elevated level growth hormone . It possible deficiency insulin-like growth factor 1 , hormone important maintenance skeletal integrity , may contribute severe osteopenia see anorexia nervosa . The physiologic effect recombinant human insulin-like growth factor 1 ( rhIGF-1 ) treatment adolescent young adult anorexia nervosa study . The goal proposal investigate effect recombinant human insulin-like growth factor 1 bone density bone microarchitecture adolescent girl young adult woman anorexia nervosa 6 month period . We hypothesize adolescent young adult anorexia nervosa patient , insulin-like growth factor 1 deficient , respond exogenously administer recombinant human insulin-like growth factor 1 elevation biochemical index bone turnover increase bone density improvement bone structure , maintain bone density ( contrast decrease bone density expect adolescent girl woman anorexia nervosa treat ) .</brief_summary>
	<brief_title>Effects rhIGF-1 Bone Metabolism Adolescent Girls With Anorexia Nervosa</brief_title>
	<detailed_description />
	<mesh_term>Anorexia Nervosa</mesh_term>
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Meet criterion anorexia nervosa ( AN ) describe Diagnostic Statistical Manual Mental Disorders Pregnant nursing Hematocrit &lt; 30 % , K &lt; 3 mmol/L Any illness ( AN ) know affect bone mineral metabolism diabetes , untreated hypo hyperthyroidism , hyperparathyroidism History use medicine , corticosteroid , know affect bone density . Subjects estrogen still eligible participate study data adult woman AN indicate deleterious effect estrogen patient receive rhIGF</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Bone density</keyword>
	<keyword>Bone turnover marker</keyword>
	<keyword>rhIGF-1</keyword>
	<keyword>Bone structure</keyword>
	<keyword>Anorexia nervosa</keyword>
</DOC>